HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI

Background Recent studies provide evidence that hepatocellular  adenomas  (HCAs) frequently take up gadoxetic acid (Gd-EOB) during the hepatobiliary phase (HBP). The purpose of our study was to investigate how to differentiate between Gd-EOB-enhancing HCAs and focal nodular hyperplasias (FNHs). We therefore retrospectively included 40 HCAs classified as HBP Gd-EOB-enhancing lesions from a sample of 100 histopathologically proven HCAs in 65 patients. These enhancing HCAs were matched retrospectively with 28 FNH lesions (standard of reference: surgical resection). Two readers (experienced abdominal radiologists blinded to clinical data) reviewed the images evaluating morphologic features and subjectively scoring Gd-EOB uptake (25–50%, 50–75% and 75–100%) for each lesion. Quantitative lesion-to-liver enhancement was measured in arterial, portal venous (PV), transitional and HBP. Additionally, multivariate regression analyses were performed. Results Subjective scoring of intralesional Gd-EOB uptake showed the highest discriminatory accuracies (AUC: 0.848 (R#1); 0.920 (R#2)— p  < 0.001) with significantly higher uptake scores assigned to FNHs (Cut-off: 75%-100%). Typical lobulation and presence of a central scar in FNH achieved an accuracy of 0.750 or higher in at least one reader (lobulation—AUC: 0.809 (R#1); 0.736 (R#2); central scar—AUC: 0.595 (R#1); 0.784 (R#2)). The multivariate regression emphasized the discriminatory power of the Gd-EOB scoring ( p  = 0.001/OR:22.15 (R#1) and p  < 0.001/OR:99.12 (R#2). The lesion-to-liver ratio differed significantly between FNH and HCA in the PV phase and HBP (PV: 132.9 (FNH) and 110.2 (HCA), p  = 0.048 and HBP: 110.3 (FNH) and 39.2 (HCA), p  < 0.001)), while the difference was not significant in arterial and transitional contrast phases ( p  > 0.05). Conclusion Even in HBP-enhancing HCA, characterization of Gd-EOB uptake was found to provide the strongest discriminatory power in differentiating HCA from FNH. Furthermore, a lobulated appearance and a central scar are more frequently seen in FNH than in HCA.

[1]  J. Zucman‐Rossi,et al.  Hepatocellular adenoma: what is new in 2008 , 2008, Hepatology international.

[2]  K. Ishak,et al.  Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. , 1979, Journal of the American Medical Association (JAMA).

[3]  H. Reeves EASL Clinical Practice Guidelines on the management of benign liver tumours. , 2016, Journal of hepatology.

[4]  B. Hamm,et al.  Evaluation of possible drug–drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP) , 2011, Journal of magnetic resonance imaging : JMRI.

[5]  C. Dejong,et al.  Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[6]  O. Matsui,et al.  Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI. , 2018, AJR. American journal of roentgenology.

[7]  C. Bartolozzi,et al.  Focal nodular hyperplasia of the liver: diffusion and perfusion MRI characteristics. , 2013, Magnetic resonance imaging.

[8]  J. Zucman‐Rossi,et al.  Genotype phenotype classification of hepatocellular adenoma. , 2007, World journal of gastroenterology.

[9]  J. Zucman‐Rossi,et al.  Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification , 2008, Hepatology.

[10]  W. Cai,et al.  Diagnostic Value of Gd-EOB-DTPA-MRI for Hepatocellular Adenoma: A Meta-Analysis , 2017, Journal of Cancer.

[11]  I. Steffen,et al.  Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics. , 2013, Magnetic resonance imaging.

[12]  R. D. de Man,et al.  [Diagnosis and treatment of hepatocellular adenoma in the Netherlands: similarities and differences]. , 2007, Nederlands tijdschrift voor geneeskunde.

[13]  P. Ros,et al.  Genetics and imaging of hepatocellular adenomas: 2011 update. Invited commentary. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[14]  Nancy A Obuchowski,et al.  Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. , 2012, AJR. American journal of roentgenology.

[15]  S. Reeder,et al.  Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid , 2012, Journal of magnetic resonance imaging : JMRI.

[16]  J. Zucman‐Rossi,et al.  Molecular classification of hepatocellular adenoma in clinical practice. , 2017, Journal of hepatology.

[17]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[18]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[19]  D. Seehofer,et al.  Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation? , 2020, European Radiology.

[20]  B. Henderson,et al.  Liver-cell adenomas associated with use of oral contraceptives. , 1976, The New England journal of medicine.

[21]  V. Paradis,et al.  A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. , 2009, Gastroenterology.

[22]  V. Katabathina,et al.  Genetics and imaging of hepatocellular adenomas: 2011 update. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[23]  I. Steffen,et al.  Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience , 2014, European Radiology.

[24]  I. Steffen,et al.  Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI , 2012, European Radiology.

[25]  J. Zucman‐Rossi,et al.  Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience , 2009, Hepatology.

[26]  H. Onaya,et al.  Ring-like enhancement of focal nodular hyperplasia with hepatobiliary-phase Gd-EOB-DTPA-enhanced magnetic resonance imaging: radiological-pathological correlation , 2011, Japanese Journal of Radiology.

[27]  T. V. van Gulik,et al.  Imaging Modalities for Focal Nodular Hyperplasia and Hepatocellular Adenoma , 2010, Digestive Surgery.

[28]  U. Motosugi,et al.  Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. , 2012, Radiology.

[29]  R. D. de Man,et al.  Diagnosis and Treatment of Hepatocellular Adenoma in the Netherlands: Similarities and Differences , 2010, Digestive Surgery.

[30]  V. Paradis,et al.  Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. , 2006, Radiology.

[31]  T. V. van Gulik,et al.  Risk factors for bleeding in hepatocellular adenoma , 2014, The British journal of surgery.

[32]  L. Barthelmes,et al.  Liver cell adenoma and liver cell adenomatosis. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[33]  Jorge M. Fuentes-Orrego,et al.  Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI. , 2014, AJR. American journal of roentgenology.

[34]  B. Naini,et al.  Qualitative and Quantitative Gadoxetic Acid-enhanced MR Imaging Helps Subtype Hepatocellular Adenomas. , 2016, Radiology.

[35]  M. Thomeer,et al.  MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver‐specific contrast agents , 2014, Journal of magnetic resonance imaging : JMRI.